Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00563810
NCT00563810
Completed
Phase 1

An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer0 sites72 target enrollmentOctober 2004
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy
DrugsMYO-029

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Healthy
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
72
Primary Endpoint
To assess safety and tolerability.
Status
Completed
Last Updated
18 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

This is a multiple dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational new drug.

Registry
clinicaltrials.gov
Start Date
October 2004
End Date
April 2006
Last Updated
18 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • •Men aged 18 to 45 years inclusive on study day
  • •Elderly men and women aged 65 to 80 years inclusive on study day
  • •Women must be postmenopausal for \> or = 1 year (with estradiol \< 25 pg/mL and an FSH \> 40 mIU/mL).
  • •Healthy as determined by the investigator on the basis of medical history, physical examination, vital signs, clinical laboratory test results, and 12-leave electrocardiogram.
  • •Elderly subjects may have stable, nonclinically significant abnormalities on physical examination, and laboratory evaluation.
  • •Non-smoker.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

To assess safety and tolerability.

Similar Trials

Completed
Phase 1
Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese SubjectsHealthy
NCT00434187Wyeth is now a wholly owned subsidiary of Pfizer24
Completed
Phase 1
Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173Healthy
NCT02217839Aspireo Pharmaceuticals Limited42
Completed
Phase 1
MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).Diabetes Mellitus, Non-Insulin-Dependent
NCT00754130Merck Sharp & Dohme LLC16
Terminated
Phase 1
Study Evaluating Multiple Ascending Dose in Schizophrenia PatientsHealthy
NCT00620568Wyeth is now a wholly owned subsidiary of Pfizer32
Completed
Phase 1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)Healthy VolunteersGeneralized Anxiety Disorder (GAD)Bipolar Disorder (BPD)
NCT06024239AbbVie72